By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Myriad Genetics, Inc. 

320 Wakara Way

Salt Lake City  Utah  84108  U.S.A.
Phone: 801-584-3600 Fax: 801-584-3640


About Myriad
Myriad is a biopharmaceutical company. We are world leaders in cancer predictive medicine. Individuals with a history of cancer in their family use these products to determine their own risk of developing cancer. In the battle against cancer, being forewarned is truly being forearmed. Risk can be managed and cancer may be averted through appropriate precautions. If diagnosed, it may be treated more successfully with a variety of proven options.

Myriad discovered the BRCA1 and BRCA2 genes that cause hereditary breast and ovarian cancer, and now offers the most accurate clinical tests available to determine predisposition to cancer: BRACAnalysis® for hereditary breast and ovarian cancer, COLARIS® for hereditary colon and endometrial cancer, COLARIS AP® for hereditary colorectal polyps and cancer, and MELARIS® for hereditary melanoma and pancreatic cancer. These tests are unparalleled in accuracy, quality and customer service.

We are also developing therapeutics in areas of critical need to address certain of the most pervasive diseases of our time. Alzheimer’s disease, cancer and AIDS are among those for which Myriad is preparing therapeutics.

Our most advanced drug candidate is FLURIZAN™, an investigational compound for Alzheimer’s disease. We are testing the drug candidate in a large, double-blinded, placebo-controlled and randomized Phase 3 clinical trial in 1600 patients with Alzheimer’s disease. The trial is enrolling now and is scheduled to complete in 2007.

In the cancer field, our most advanced drug development program is MPC-7869 for prostate cancer. The Phase 2/3 trial is in its third and final year of study, scheduled to complete in mid-year 2006. MPC-7869 modulates the signal transduction and transcription activation pathways associated with nuclear factor kappa B (NFkB), a principle transcription factor in the expression of many molecules involved in cell growth/death and inflammation. MPC-7869 has demonstrated anti-tumor activity in animal models of prostate and colon cancer and has been well-tolerated in clinical studies in prostate cancer patients.

Two additional anti-cancer drug candidates are in clinical development at Myriad. Each causes cancer cells to commit suicide, but they act at different points in the process. In laboratory studies with MPC-6827, the compound was more effective than the standard of care drugs in killing cancer cells from the breast, colon, pancreas, ovary and skin. MPC-6827 also has the ability to cross the blood/brain barrier to a remarkable extent. In preclinical testing the compound achieved a level that was 1500 times higher in the brain than in the blood. That level compares to the best of current cancer drugs that reaches only 30% of its blood concentration in the brain. MPC-6827 is being studied in a Phase 1 trial at M.D. Anderson Cancer Center in patients with tumors that have metastasized to the brain. It is also being studied in a second Phase 1 trial in patients with solid tumors of many different types. The trials help determine safety and pharmacokinetic aspects of the drug candidate.

MPC-2130 acts at an earlier point in the apoptosis (cell death) pathway. The Phase I clinical study is designed to evaluate the safety and pharmacokinetic profile of MPC-2130 in patients with advanced metastatic tumors or blood cancers as well as refractory cancer that has progressed despite previous chemotherapy. In preclinical studies MPC-2130 has demonstrated significant cancer cell killing activity in ovarian cancer, prostate cancer and two lymphoma cell lines, Burkitt's lymphoma and T-cell lymphoma. MPC-2130 was also evaluated in xenograft mouse models of ovarian cancer and prostate cancer. The drug candidate reduced growth of ovarian cancer tumors by 61% relative to controls. MPC-2130 was also effective in demonstrating a significant reduction in tumor volumes in mice implanted with human prostate cancer.

Importantly, MPC-2130 was shown to be highly effective in cancer cell lines that are resistant to multiple drugs. Cancer cells may become resistant to chemotherapy through a cellular function that actively purges drug from the cell. The function is carried out by MDR pumps and is the primary cause of cancers' resistance to many marketed drugs such as paclitaxel and vinblastine. MPC-2130 was tested to determine its susceptibility to MDR pumps, and was shown to be equally effective in anti-cancer activity against the MDR cell lines tested, suggesting that the drug candidate is not a substrate for MDR pumps.

Myriad researchers have many significant innovations to their credit. One such advancement in understanding of the human-virus interaction led to the development of MPI- 49839, the first member of a novel class of drugs with a novel mechanism, inhibiting the assembly of new virus from components. In testing, the virus cannot complete development and is unable to escape from the cell, preventing the spread of infection. The compound is slated for IND submission to the FDA prior to beginning human clinical trials in the first half of 2006.

Early stage therapeutic development programs at Myriad are shedding light on diseases of great interest. We will continue to strive to transform the possibilities that these discoveries bring forth to create the medicines that will improve patients’ lives.

We encourage you to explore our web site to learn about the people and products that make Myriad what it is today and what it will become tomorrow.

Working at Myriad
At Myriad, we provide you with health and security for you and your family. In addition to competitive salaries and opportunities for professional development and advancement, full time employees enjoy benefit programs intended to enhance job satisfaction.

Myriad benefit programs include paid personal leave time, 12 paid holidays, excellent medical and dental insurance programs, as well as a stock purchase plan and incentive stock options. Myriad also provides a comprehensive 401k plan, plus provides basic life and accident insurance, short and long term disability insurance, tax free reimbursement accounts (Section 125 Cafeteria Plan), as well as other Company benefits.

Situated in the foothills of the Wasatch Mountains, you'll enjoy breathtaking views at work and an incredible lifestyle away from the office. Myriad is located just footsteps away from Red Butte Gardens, (Utah's Botanical Garden and Arboretum) and the University of Utah campus. Utah is home to some of the best downhill skiing and snow boarding in the country, with 14 ski resorts in Utah and over 500 inches annually of dry, light snow. Salt Lake City has a wide variety of high quality restaurants, cultural activities such as the theater, ballet and symphony, and the Jazz NBA Basketball team. In your spare time, you might choose to mountain bike for a weekend in Moab or at lunchtime on a trail a few yards from Myriad's back door.

Myriad was established in 1991, became a public company in 1995 and is traded on Nasdaq under the symbol MYGN. We have four commercial products and a 100+ person professional oncology products sales force.

Employment Opportunities
See our Web site at: for current job listings or write:

Myriad Genetics, Inc.
Attn: Human Resources
320 Wakara Way
Salt Lake City, UT 84108
Fax: 801-584-3741
No phone calls please.
Equal Opportunity Employer.

Last Updated: 01-06-2006

Key Statistics

Ownership: Public

Web Site: Myriad Genetics
Symbol: MYGN

Company News
Myriad Genetics (MYGN) To Announce Fiscal Fourth-Quarter 2016 Financial Results On August 9 7/27/2016 8:10:47 AM
Myriad Genetics (MYGN)’s myChoice HRD Test Successfully Identifies Patients That Meet Primary Endpoint In Tesaro (TSRO)’s Pivotal Phase 3 Ovarian Cancer Study With Niraparib 6/29/2016 6:58:24 AM
Myriad Genetics (MYGN) Board Approves $200 Million Increase In Share Repurchase Program 6/7/2016 1:52:16 PM
ASCO2016: Myriad Genetics (MYGN) Will Present Three New Hereditary Cancer Studies At The ASCO Annual Meeting 6/6/2016 3:45:40 PM
ASCO2016: Myriad Genetics (MYGN) myRisk Hereditary Cancer Test Demonstrates The Magnitude Of Breast And Ovarian Cancer Risk In Nearly 100,000 Patients 6/6/2016 3:01:28 PM
Myriad Genetics (MYGN) Snaps Up Sividon Diagnostics in $56 Million Deal 6/1/2016 8:05:11 AM
Myriad Genetics (MYGN)’ Statement On HIPAA Complaint From Four Patients 5/20/2016 8:08:47 AM
Myriad Genetics (MYGN) To Present New Research At The 2016 ASCO Annual Meeting 5/19/2016 10:35:22 AM
Myriad Genetics (MYGN) Announces Plans To Launch A Web Portal For Patients That Will Provide Access To Test Results, Tools And Health Information 5/19/2016 10:34:46 AM
Myriad Genetics (MYGN) To Present Three New Studies At The American Urological Association Annual Meeting 5/6/2016 8:13:18 AM